Kuros Biosciences AG Overview
Pro stress-test →Kuros Biosciences is a Swiss biotech company developing innovative orthobiologic products focused on spinal fusion and bone regeneration. The company's lead commercial product, MagnetOs, is a synthetic bone graft with advanced submicron surface technology that has been used in over 10,000 spinal fusion surgeries across three continents. Kuros addresses a significant clinical need in managing spine-related pain and non-union complications.
Strategic Profile
Pro stress-test →Kuros positions itself as a next-generation leader in orthobiologics with proprietary patent-protected bone graft technologies and a drug-biologic pipeline. The company has built distribution agreements across Europe and the US, with operations in Switzerland, Netherlands, and Massachusetts. Its strategic competitive advantage lies in its MagnetOs osteoinductive technology and advancement of Fibrin-PTH, the first drug-biologic combination for interbody spinal fusions.
Competitive Landscape
Pro stress-test →Kuros competes in orthobiologics against larger medical device companies including Medtronic, NuVasive, Zimmer Biomet, and smaller biotech firms. The company's differentiation is based on proprietary submicron surface technology and novel drug-biologic combinations. The spinal fusion market is highly competitive but large ($3B+ annual opportunity), with Kuros focused on premium MagnetOs positioning and Fibrin-PTH's first-mover advantage in drug-biologic combinations.
Industry Context
Kuros Biosciences AG operates in Orthobiologics/Medical Devices - Spinal Fusion.
Key facts
Founded: 2016 · Headquarters: Schlieren, Switzerland · Employees: 66